The Microbiome in Systemic Sclerosis: Pathophysiology and Therapeutic Potential.
Ontology highlight
ABSTRACT: Systemic sclerosis (SSc), also known as scleroderma, is an autoimmune disease with unknown etiology characterized by multi-organ fibrosis. Despite substantial investigation on SSc-related cellular and molecular mechanisms, effective therapies are still lacking. The skin, lungs, and gut are the most affected organs in SSc, which act as physical barriers and constantly communicate with colonized microbiota. Recent reports have documented a unique microbiome signature, which may be the pathogenic trigger or driver of SSc. Since gut microbiota influences the efficacy and toxicity of oral drugs, evaluating drug-microbiota interactions has become an area of interest in disease treatment. The existing evidence highlights the potential of the microbial challenge as a novel therapeutic option in SS
SUBMITTER: Kim S
PROVIDER: S-EPMC9853331 | biostudies-literature | 2022 Dec
REPOSITORIES: biostudies-literature
ACCESS DATA